Jump to Main Content

Programs

Scientific Workshops

Scientific Workshop on Infectious Disease and Coagulation

December 2, 2020,  7:00 a.m. - 10:00 a.m. Pacific time

Co-Chair:

Shannon Meeks, MD
Emory University
Atlanta, GA

NOTE: PER THE REQUEST OF THE WORKSHOP ORGANIZERS, PRESENTATIONS WILL BE AVAILABLE FOR ON-DEMAND VIEWING UNTIL DECEMBER 10, 2020 at 11:59 P.M. EASTERN TIME

The ongoing COVID-19 pandemic has highlighted the need for ongoing information-sharing between hematologists, infectious disease experts, immunologists, coagulation laboratorians, and public health officials. Severe COVID-19 is often marked by an inflammatory response that leads to coagulation abnormalities and increased risk of venous and arterial clotting abnormalities. This inflammatory response and subsequent perturbations in hemostasis is not limited to COVID-19 and has been seen in the context of other viral and bacterial infections. Furthermore, the increased risk of venous and arterial clotting abnormalities is known to occur in the context of infectious disease and often requires anti-thrombotic treatment considerations.

This workshop will provide a forum for experts in a variety of fields to share information at the intersection of coagulation and infectious disease, highlighting similarities and differences between COVID-19 and previously studied infections. The workshop will be a broad-reaching session that will cover basic science, clinical translation, and public health impact – providing attendees with the opportunity to better understand the potential biological mechanisms underlying the pathophysiology of COVID-19, how understanding those biologic mechanisms may be able to improve patient care, and how modifications in patient care may be able to affect public health.

Target Audience: The target audience for this workshop will be consultant hematologists providing care for patients with underlying infections, particularly those with a specific interest in understanding the pathophysiology of the immunohemostatic response in the context of infection and those with interest in applying knowledge of pathophysiology to improve treatment.

Objectives:

  1. Increase understanding of pathophysiology underlying the immunohemostatic response in the context of infectious disease.
  2. Share information regarding therapeutic options to prevent and/or treat aberrant immunohemostatic responses to infectious pathogens.
  3. Provide a forum for cross-talk between experts in a variety of fields, including hematology, immunology, laboratory science, and public health, so that relevant information is made available to all parties charged with responding to infectious disease outbreaks linked to coagulation abnormalities.

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

Workshop Schedule


Moderator:

Shannon Meeks, MD
Emory University
Atlanta, GA

Moderator:

Robert F. Sidonio Jr., MD, MSc.
Emory University
Atlanta, GA

Speakers:

Ed Pryzdial, PhD
Centre for Blood Research, University of British Columbia
Vancouver, Canada
The Immunohemostatic Response to Infection Overview

Robert A. Campbell, PhD
University of Utah
Salt Lake City, UT
Dengue Fever and COVID-19

Jamie M. O'Sullivan, PhD
Royal College of Surgeons Ireland
Dublin, Ireland
Malaria and COVID-19

Moderator:

Amanda B Payne, PhD,MPH
Centers for Disease Control and Prevention
Atlanta, GA

Speakers:

Jean M. Connors, MD
Brigham & Women's Hospital, Dana Farber Cancer Institute
Boston, MA
Prevention and Treatment of Adverse Hemostatic Outcomes in Infectious Disease

Jerrold H Levy, MD
Duke University Medical Center
Durham, NC
The Role of the Coagulation Laboratory in Treating the Infectious Disease Patient

Cheryl Maier, MD, PhD
Emory University School of Medicine
Atlanta, GA
Monitoring for Adverse Hemostatic Outcomes at the Population Level

Moderators:

Amanda B Payne, PhD,MPH
Centers for Disease Control and Prevention
Atlanta, GA

Robert F. Sidonio Jr., MD, MSc.
Emory University
Atlanta, GA

Shannon Meeks, MD
Emory University
Atlanta, GA

Craig Hooper
Centers for Disease Control and Prevention
Atlanta, GA

Moderator:

Shannon Meeks, MD
Emory University
Atlanta, GA

back to top

Scientific Workshop on Myeloid Development

December 2, 2020,  7:00 a.m. - 10:00 a.m. Pacific time

Co-Chair:

Ross L. Levine, MD
Memorial Sloan Kettering Cancer Center
New York, NY

NOTE: PER THE REQUEST OF THE WORKSHOP ORGANIZERS, PRESENTATIONS WILL BE AVAILABLE FOR ON-DEMAND VIEWING UNTIL DECEMBER 10, 2020 at 11:59 P.M. EASTERN TIME

This workshop will examine the latest scientific findings in myeloid biology in a highly interactive environment that permits the exchange of ideas among investigators. It will focus on topics such as hematopoietic stem cell biology, leukemogenesis, cell signaling, transcription factors, epigenetic effects, and other topics related to myeloid biology. Each session leader will briefly summarize the current questions facing the field and then lead discussions on how best to answer those questions. New findings on novel techniques that provide insight into these questions will be an essential part of all discussions. The research presented at this workshop will also focus on the use of molecular biology and biochemistry tools, as well as animal models, to address the core topics. This workshop will not include any purely clinical, epidemiologic, or population-based approaches and will feature brief didactic sessions followed by a brief period for questions and answers.

Target Audience: This workshop is directed at laboratory-based investigators, and is meant to also attract young investigators, who will have an opportunity to interact directly with experts in the field. In addition, the broad-ranging content and highly interactive format of this workshop might also appeal to clinically oriented investigators.

Objectives:

  1. Discuss the latest scientific developments in hematopoietic stem cell biology, leukemogenesis, cell signaling, transcription factors, epigenetic effects, and other topics related to myeloid biology.
  2. Have interactive presentations by world-class scientists.
  3. Provide young investigators opportunities to interact with world-renowned experts in the field.

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

Workshop Schedule


Co-Chair:

Ross L. Levine, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Speaker:

Ross L. Levine, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Opening Remarks

Moderator:

Eric Pietras, PhD
University of Colorado
Aurora, CO

Speakers:

Heather A. O'Leary, PhD
Indiana University School of Medicine
Indianapolis, IN
Gene Expression, Proteomic and Functional Landscape of Hematopoiesis in Low-Oxygen Conditions

Heather A. O'Leary, PhD
Indiana University School of Medicine
Indianapolis, IN
Live Q&A

Isabel Beerman, PhD
National Institute on Aging, NIH
Baltimore, MD
Impact of Caloric Restriction on Transcriptional and Epigenetic Regulation in Hematopoietic Stem Cells

Isabel Beerman, PhD
National Institute on Aging, NIH
Baltimore, MD
Live Q&A

Michalis Agathocleous, PhD
UT Southwestern Medical Center
Dallas, TX
Ascorbate Suppresses Myelopoiesis and Regulates the Hematopoietic Response to Infection (CANCELLED)

Michalis Agathocleous, PhD
UT Southwestern Medical Center
Dallas, TX
Live Q&A (CANCELLED)

Amar Desai, PhD
Case Western Reserve University
Cleveland, OH
Regulation of the Hematopoietic Niche By 15-PGDH

Amar Desai, PhD
Case Western Reserve University
Cleveland, OH
Live Q&A

Moderator:

Benjamin L. Ebert, MD,PhD
Harvard Medical School
Boston, MA

Speakers:

Ann-Kathrin Eisfeld, MD
The Ohio State University
Columbus, OH
Poor Treatment Outcomes of Young (<60 Years) African American Patients Diagnosed with Acute Myeloid Leukemia (CANCELLED)

Ann-Kathrin Eisfeld, MD
The Ohio State University
Columbus, OH
Live Q&A (CANCELLED)

Peter van Galen, PhD
Brigham and Women's Hospital
Boston, MA
Tracing the Evolution of Myeloid Malignancies Using Single Cell Sequencing

Peter van Galen, PhD
Massachusets General Hospital
Boston, MA
Live Q&A

Sergei Doulatov, PhD
University of Washington
Seattle, WA
Mechanisms of Ring Sideroblast Formation in SF3B1-Mutant Myelodysplastic Syndrome

Sergei Doulatov, PhD
University of Washington
Seattle, WA
Live Q&A

Anna S Nam, MD
Weill Cornell Medicine
New York, NY
Single-Cell Multi-Omics in Human Clonal Hematopoiesis Reveals That DNMT3A R882 Mutations Perturb Early Progenitor States through Selective Hypomethylation

Anna S Nam, MD
Weill Cornell Medicine
New York, NY
Live Q&A

Moderator:

Ulrich G. Steidl, MD/PhD
Albert Einstein College of Medicine
Bronx, NY

Speakers:

Olga A Guryanova, MD,PhD
University of Florida College of Medicine
Gainesville, FL
Leukemia-Associated DNMT3A Mutations Drive Functional and Epigenetic Heterogeneity of Hematopoiesis

Olga A Guryanova, MD,PhD
University of Florida College of Medicine
Gainesville, FL
Live Q&A

Ly Vu, PhD
Simon Fraser University
Burnaby, BC, Canada
Gene Expression Control By the CCR4-NOT (CNOT) RNA Deadenylation Complex in Acute Myeloid Leukemia

Ly Vu, PhD
Simon Fraser University
Burnaby, BC, Canada
Live Q&A

Meritxell Alberich-Jorda
Institute of Molecular Genetics of the Czech Academy of Sciences
Prague, Czech Republic
Beta-Catenin-TCF/LEF-Mediated Transcription Fine Tunes Granulopoiesis in Steady-State and Emergency Granulopoiesis

Meritxell Alberich-Jorda
Institute of Molecular Genetics of the Czech Academy of Sciences
Prague, Czech Republic
Live Q&A

Aditi Shastri, MD
Albert Einstein College of Medicine/Montefiore Medical Center
Astoria, NY
Therapeutic Targeting of STAT3 in MDS and AML Stem Cells

Aditi Shastri, MD
Albert Einstein College of Medicine/Montefiore Medical Center
Astoria, NY
Live Q&A

Moderator:

Claudia Lengerke, MD
University Hospital Basel
Basel, Switzerland

Speakers:

Teresa V. Bowman, PhD
Albert Einstein College of Medicine, Montefiore Medical Center
Bronx, NY
Excessive R-Loops Trigger an Inflammatory Cascade Leading to Aberrant HSPC Expansion

Teresa V. Bowman, PhD
Albert Einstein College of Medicine, Montefiore Medical Center
Bronx, NY
Live Q&A

R. Grant Rowe, MD, PhD
Boston Children's Hospital
Boston, MA
Lin28b/Let-7 Implements Juvenile Hematopoiesis Via Regulation of the Polycomb Repressor Complex Component Cbx2

R. Grant Rowe, MD, PhD
Boston Children's Hospital
Boston, MA
Live Q&A

Julia Skokowa, MD, PhD
University Hospital Tuebingen
Tuebingen, Germany
GADD45b-Dependent RXRa Demethylation Is Essential for G-CSF-Triggered Granulopoiesis

Julia Skokowa, MD, PhD
University Hospital Tuebingen
Tuebingen, Germany
Live Q&A

Adrienne M. Dorrance, PhD
The Ohio State University
Columbus, OH
The Role of EGFL7 in Healthy and Malignant Hematopoiesis

Adrienne M. Dorrance, PhD
The Ohio State University
Columbus, OH
Live Q&A

Co-Chair:

Patricia A Ernst, PhD
University of Colorado
aurora, CO

Speaker:

Patricia A Ernst, PhD
University of Colorado Denver/Anschutz Medical Campus
Aurora, CO
Closing Remarks

back to top

Scientific Workshop on Tumor Immune Interactions in Lymphoid Malignancies

December 2, 2020,  7:00 a.m. - 10:00 a.m. Pacific time

Co-Chair:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

NOTE: PER THE REQUEST OF THE WORKSHOP ORGANIZERS, PRESENTATIONS WILL BE AVAILABLE FOR ON-DEMAND VIEWING UNTIL DECEMBER 10, 2020 at 11:59 P.M. EASTERN TIME

The area of immunotherapy in lymphoid malignancies has exploded in recent years. Multiple new immune therapies are in development in lymphoproliferative diseases, and this exciting progress has been due to an increased understanding of the tumor microenvironment and tumor-immune interactions in these diseases. This proliferation of scientific knowledge has led to multiple potential new treatments, including new immune checkpoint blockade therapies, novel T-cell approaches, agents targeting monocytes, and macrophages, as well as new approaches inhibiting immune receptors and cytokine signaling.

The workshop’s aim is to have scientists, translational researchers, and clinicians “hear it here first” when it comes to the next big thing in the management of lymphoid diseases. This workshop will be highly interactive and somewhat speculative (though based on science), with a strong focus on future translation of immune-related research into the clinic.

Target Audience: The target audience for this workshop is laboratory-based investigators who are interested in lymphoid biology. The workshop’s presentations and discussions focus solely on the basic science surrounding the development of lymphoid malignancies; there are no presentations on clinical/treatment strategies. Attendees benefit from interactive presentations by world-class scientists. The workshop reinforces the appeal of attending the ASH annual meeting by scientists from around the world, and it can serve as an introduction to the scientific content that will be presented at the ASH annual meeting.

Objectives:

  1. Highlight novel basic science and translational immune research in lymphoid malignancies that are likely to translate in the near future to clinically relevant therapies, biomarkers, or correlative science.
  2. Feature new methods of immune monitoring, as well as potential future therapies or therapeutic targets that are likely to be important in lymphoid malignancies.

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

Workshop Schedule


Moderator:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Moderators:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Ronald Levy, MD
Stanford Univ. School of Medicine
Stanford, CA

Speakers:

Max S. Topp, MD
Universitätsklinikum Würzburg
Würzburg, Germany
Current Results with BITEs and Bispecific Antibodies in Lymphoid Malignancies

Max S. Topp, MD
Universitätsklinikum Würzburg
Würzburg, Germany
Live Q&A

Jeffrey S. Miller, MD
University of Minnesota
Minneapolis, MN
BIKEs, TRIKEs, and SMITEs

Jeffrey S. Miller, MD
University of Minnesota
Minneapolis, MN
Live Q&A

Laurie H. Sehn, MD, MPH
BC Cancer and The University of British Columbia
Vancouver, BC, Canada
CD19 Antibodies and CD79-Directed ADCs in B-cell Malignancies

Laurie H. Sehn, MD, MPH
BC Cancer Centre for Lymphoid Cancer, University of British Columbia
vancouver, BC, Canada
Live Q&A

Moderators:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Ronald Levy, MD
Stanford Univ. School of Medicine
Stanford, CA

Speakers:

Jeremy S. Abramson, MD, MMSc
Massachusetts General Hospital
Boston, MA
Current Results with CAR T-cells in Lymphoid Malignancies

Jeremy S. Abramson, MD, MMSc
Massachusetts General Hospital
Boston, MA
Live Q&A

Larry W. Kwak, MD, PhD
City of Hope Comprehensive Cancer Center
Duarte, CA
CD22 and BAFF-R-Directed CAR T-Cells

Larry W. Kwak, MD, PhD
City of Hope Comprehensive Cancer Center
Duarte, CA
Live Q&A

Katayoun Rezvani, MD,PhD
MD Anderson Cancer Center
Houston, TX
NK CAR-cells and Allogeneic CAR T-cells

Katy Rezvani, MD,PhD
MD Anderson Cancer Center
Houston, TX
Live Q&A

Moderator:

Ronald Levy, MD
Stanford University Medical Center
Stanford, CA

back to top

Scientific Workshop on Epidemiology: Disparities in Hematologic Diseases: Risk, Outcomes and Care

Thursday, December 3, 2020,  2:00 p.m. - 4:35 p.m. Pacific time

Co-Chairs:

James R. Cerhan, MD, PhD
Mayo Clinic
Rochester, MN

James M. Foran, MD
Mayo Clinic
Jacksonville, FL

Wendy Cozen, DO, MPH
University of California, Irvine
Irvine, CA

Neil A. Zakai, MD,MSc
Larner College of Medicine at the University of Vermont
Burlington, VT

NOTE: PER THE REQUEST OF THE WORKSHOP ORGANIZERS, PRESENTATIONS WILL BE AVAILABLE FOR ON-DEMAND VIEWING UNTIL DECEMBER 10, 2020 at 11:59 P.M. EASTERN TIME

This workshop fills a critical gap in the meeting in the areas of epidemiology and population science. The workshop this year focuses on racial/ethnic disparities in non-malignant and malignant hematologic diseases, covering the spectrum from descriptive epidemiology on risk and survival patterns by race/ethnicity, to underlying causes of racial/ethnic disparities. The workshop will provide a forum for epidemiologists, clinicians and basic scientists interested in disparities to come together to present and discuss current knowledge and future directions in this timely area. The theme is highly relevant for ASH to incorporate consideration of disparities into hematologic research and clinical applications going forward.

The workshop is divided into three sessions, lymphoid and myeloid malignant hematology, non-malignant hematology including venous and arterial thrombosis, hematologic autoimmune disorders and hemostasis and a session on epidemiological aspects of hematology-related disparities in the setting of COVID-19 infection.  The talks include descriptive patterns, risk factors and biological mechanisms related to disparities, participation in trials, comorbidities and other relevant issues around race and outcomes. There will be time allocated for discussion following each of the talks.

Specific topics will include updates on disparities in risk and survival patterns for lymphoid and myeloid neoplasms from SEER and WHO data, molecular epidemiology studies of genetic and environmental risk factors for lymphoid and myeloid malignancies and the extent to which these explain disparities, differences in coagulopathies by race/ethnicity and how much is explained by access to care vs. underlying biology, and racial/ethnic differences in immunity and comorbidities as underlying causes of differences in COVID-19 outcomes, among others.

Target Audience: The target audience comprises trainees and researchers interested in learning more about disparities in the context of population science and how the issues around disparities can be applied to basic science and clinical research, clinical care and health policy. In addition, epidemiologists and other population scientists working in hematology will benefit by hearing the latest up to date research presentations and interacting with colleagues.

Objectives:

  1. To provide a unique forum at the ASH annual meeting to present and discuss advances in the field of epidemiology of hematologic diseases, with a focus on disparities.
  2. To provide information on areas where there is a knowledge gap and where more research is needed.
  3. To promote research on disparities among investigators with established research programs.
  4. To promote interest among trainees for consideration of this area of study.
  5. To facilitate discussion with the end-goal of stimulating new collaborations in the areas of disparities that advance the study of epidemiology and disease control.

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

Workshop Schedule


Chair:

Wendy Cozen, DO, MPH
University of California, Irvine
Irvine, CA

Co-Chairs:

Neil A. Zakai, MD,MSc
Larner College of Medicine at the University of Vermont
Burlington, VT

James R. Cerhan, MD, PhD
Mayo Clinic
Rochester, MN

James M. Foran, MD
Mayo Clinic
Jacksonville, FL

Moderators:

James R. Cerhan
Mayo Clinic
Rochester, MN

James M. Foran, MD
Mayo Clinic
Jacksonville, FL

Wendy Cozen, DO, MPH
University of California, Irvine
Irvine, CA

Speakers:

Wendy Cozen, DO, MPH
University of California, Irvine
Irvine, CA
Demographic Risk Patterns for Mature Lymphoid Malignancies

Christopher Flowers, MD,MS
The University of Texas M.D. Anderson Cancer Center
Houston, TX
Disparities in DLBCL Risk and Outcomes

Kimberly A Bertrand, ScD
Boston University
Boston, MA
Racial Disparities in MGUS and Multiple Myeloma: Epidemiologic Insights

Pinkal Desai, MD, MPH
Weill Cornell Medical College
New York, NY
Racial Disparities in Myeloid Malignancies

Adam J de Smith, PhD
University of Southern California
Los Angeles, CA
Racial/Ethnic Disparities in the Risk of Acute Lymphoblastic Leukemia

Sikander Ailawadhi, MD
Mayo Clinic
Jacksonville, FL
Racial Disparities in Outcomes of Lymphoid Malignancies: Paving a Path Forward

Moderators:

Mary Cushman, MD, MSc
Larner College of Medicine at the University of Vermont
Burlington, VT

Neil A. Zakai, MD,MSc
Larner College of Medicine at the University of Vermont
Burlington, VT

Speakers:

Neil A. Zakai, MD,MSc
Larner College of Medicine at the University of Vermont
Burlington, VT
Region, Race, and Venous Thromboembolism: The Canary in a Coal Mine

Deirdra Terrell, PhD, MPH
University of Oklahoma Health Sciences Center
Oklahoma City, OK
Racial Disparities in Immune Thrombotic Thrombocytopenic Purpura (TTP)

Mary Cushman, MD, MSc
Larner College of Medicine at the University of Vermont
Burlington, VT
Racial Differences in Stroke Impacting Black Americans

Cindy Neunert, MD
Columbia University Medical Center
New York, NY
Health Outcome Disparities in Pediatric Benign Hematology

Moderators:

James R. Cerhan, MD, PhD
Mayo Clinic
Rochester, MN

James M. Foran, MD
Mayo Clinic
Jacksonville, FL

Neil A. Zakai, MD,MSc
Fletcher Allen Health Care, University of Vermont
Burlington, VT

Wendy Cozen, DO, MPH
University of California, Irvine
Irvine, CA

back to top

Scientific Workshop on Hematology & Aging: Exploring Biomarkers, CHIP, CAR-T and Clotting

Thursday, December 3, 2020,  2:00 p.m. - 5:00 p.m. Pacific time

Co-Chairs:

Andrew Artz, MD, MS
City of Hope
Duarte, CA

Ashley Rosko, MD
The Ohio State University
Columbus, OH

NOTE: PER THE REQUEST OF THE WORKSHOP ORGANIZERS, PRESENTATIONS WILL BE AVAILABLE FOR ON-DEMAND VIEWING UNTIL DECEMBER 10, 2020 at 11:59 P.M. EASTERN TIME

Older adults with hematologic disorders are a growing demographic, where the aging population is understudied and vulnerable to both cancer- and age-related morbidity and mortality. Improving the approach to older adult cancer care requires appreciation of the basic science of aging as well as differences in disease diagnosis, response, and tolerance to treatment. Understanding the impact of aging on hematologic disease pathogenesis, response to treatment, and tolerance of therapy is an emerging area of science. This workshop aims to highlight key scientific advances in the aging and hematology field, set in the context of both non-malignant and malignant hematologic disorders. In addition, the workshop aims to partner the aging investigators within ASH with key participants in the geoscience community to advance research and improve outcomes for older adults with hematologic disorders.

Target Audience:

 The target audience includes laboratory-based investigators and clinician investigators with an interest in aging and hematology. However, the wide-ranging content, thematic focus, and interactive format may appeal to a broader audience including young investigators.

Objectives:

  1. Provide a forum within ASH for presentation of novel research related to the biology of aging and hematologic disorders.
  2. Exploration of aging biomarker integration and identification of new approaches needed to answer scientific queries evaluating the intersection of hematologic disorders and aging.
  3. Foster collaboration and engagement among aging scientists and investigators targeting thrombosis and aging.

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

Workshop Schedule


Moderators:

Andrew Artz, MD, MS
City of Hope
Duarte, CA

Ashley Rosko, MD
The Ohio State University
Columbus, OH

Moderators:

Michelle Lavin, MB, PhD, FRCPath
Royal College of Surgeons, Ireland
Dublin 2, Ireland

Anna Parks, MD
University of California, San Francisco
San Francisco, CA

Speakers:

Anna L. Parks, MD
University of California, San Francisco
San Francisco, CA
Session Introduction

Matthew T. Rondina, MD
University of Utah Health
Salt Lake City, UT
Platelets and Inflammation During Aging

Siobhan Glavey, MD, PhD, FRCPath
Beaumont &amp; Connolly Hospitals
Dublin, Ireland
VTE Risk Assessment in Patients with Myeloma: Equal for All Ages?

Sophie Susen, MD; PhD
Lille University Hospital
Lille, France
The Clinical Challenges of Angiodysplasia, Aortic Stenosis and Acquired Von Willebrand Syndrome

Siobhan Glavey, MD,PhD, FRCPath
Beaumont Hospital
Dublin, Ireland
Live Q&A and Panel Discussion

Moderators:

Rebecca L. Olin, MD
University of California, San Francisco
San Francisco, CA

Bindu Kanapuru, MD
U.S. Food and Drug Administration
Vienna, VA

Speakers:

Rebecca L. Olin, MD
University of California, San Francisco
San Francisco, CA
Session Introduction

Judith Feucht, MD
Memorial Sloan Kettering Cancer Center
New York, NY, Germany
Senolytic CAR T Cells Reverse Senescence-Associated Pathologies

Jordan Gauthier, MD
University of Washington, Seattle Cancer Care Alliance
Seattle, WA
Age, Performance Status, and Comorbidities in Relation to IEC-Associated Toxicities (Including ICANS)*

Judith Feucht, MD
Memorial Sloan Kettering Cancer Center
New York, NY, Germany
Live Q&A and Panel Discussion

Moderators:

Smith Giri, MD,MS
University of Alabama at Birmingham
Birmingham, AL

Tanya M. Wildes, MD,MSc
Washington University School of Medicine
St Louis, MO

Speakers:

Tanya M. Wildes, MD,MSc
Washington University School of Medicine
St. Louis, MO
Session Introduction

Bharat Thyagarajan, MD, PhD, MPH
University of Minnesota
Minneapolis, MN
Molecular Biomarkers of Aging

Christin Burd, PhD
The Ohio State University
Columbus, OH
Consequences of Transplant on T-cell Aging

Geoffrey Fell, PhD
Dana-Farber Cancer Institute
Boston, MA
Working Toward Molecular Measures of Frailty for Patients with Blood Cancers

Bharat Thyagarajan, MD, PhD, MPH
University of Minnesota
Minneapolis, MN
Live Q&A and Panel Discussion

Moderators:

Melissa Loh, MBBCHBAO
University of Rochester Medical Center
Rochester, NY

Rebecca L. Olin, MD
University of California, San Francisco
San Francisco, CA

Speakers:

Melissa Loh, MBBCHBAO
University of Rochester Medical Center
Rochester, NY
Session Introduction

Cynthia E. Dunbar, MD
National Heart, Lung, and Blood Institute
Bethesda, 
CHIP in Non-Humane Primates (TET2 Hyperinflammation)

Daohong Zhou
University of Florida
Gainesville, FL
Role of Cellular Senescence in Hematopoietic Stem Cell Aging

Jennifer Trowbridge, PhD
The Jackson Laboratory
Bar Harbor, ME
CHIP and the Aging Microenvironment

Zoe McQuilten, PhD
Monash University
Melbourne, Australia
The ASPREE (ASPirin in Reducing Events in the Elderly) CHIP Sub-Study

Cynthia E. Dunbar, MD
National Heart, Lung, and Blood Institute, National Institutes of Health
Bethesda, MD
Live Q&A and Panel Discussion

Moderators:

Andrew Artz, MD
City of Hope
Duarte, CA

Ashley Rosko, MD
The Ohio State University
Columbus, OH

back to top

Scientific Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma

Thursday, December 3, 2020,  7:00 a.m. - 10:00 a.m. Pacific time

Co-Chair:

Philip L. McCarthy, MD
Roswell Park Comprehensive Cancer Center
Buffalo, NY

NOTE: PER THE REQUEST OF THE WORKSHOP ORGANIZERS, PRESENTATIONS WILL BE AVAILABLE FOR ON-DEMAND VIEWING UNTIL DECEMBER 10, 2020 at 11:59 P.M. EASTERN TIME

This workshop, organized by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup, continues the yearly presentations of the latest scientific translational findings in the immunology and molecular biology of plasma cell disorders (PCDs) with emphasis on multiple myeloma and related monoclonal plasma cell diseases.

The workshop consists of 4 sessions with each session featuring four to five 10-minute basic science, translational and clinical presentations. Each session will be chaired by a leader who will summarize the current state of the field and facilitate discussion with the audience and the speakers.

Target Audience: 

This workshop is directed toward basic science, clinical, and translational investigators in the field of PCD. It is designed to be interactive with an emphasis on understanding the biology of PCD so as to develop new translational strategies to bring to the clinic from the laboratory. Trainees and junior investigators are encouraged to attend this workshop so as to interact with experts in PCD.

Objectives:

  1. Discuss the latest scientific developments in PCDs with an emphasis on the immunology and molecular biology of PCDs.
  2. Presentation of the most current trial results and issues related to IP and MRD testing in MM
  3. Understanding Trial Design for future trials and FDA and EMA approval of new MM therapies
  4. Developing new strategies for IP and MRD testing in MM, especially for standardizing testing for
    widespread applicability
  5. Encourage interaction of investigators from around the world.
  6. Encourage trainees and investigators to participate in the discussion of presentations of experts in the field of PCDs.

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

Workshop Schedule


Moderator:

Philip L. McCarthy, MD
Roswell Park Comprehensive Cancer Center
Buffalo, NY

Moderator:

Sarah A. Holstein, MD,PhD
University of Nebraska Medical Center
Omaha, NE

Speakers:

Sarah A. Holstein, MD,PhD
University of Nebraska Medical Center
Omaha, NE
MRD Practices Survey Data

Nicole J. Gormley, MD
U.S. Food and Drug Administration
Bethesda, MD
Regulatory Considerations Surrounding Novel Endpoints and Biomarker-Driven Clinical Trials in Myeloma

Pierre Demolis, MD, PhD
European Medicines Agency
Paris, Finland
EMA Perspective of Integrating MRD into Clinical Trial Design and Clinical Practice in Multiple Myeloma Therapy

Francesca Gay, MD
Citta' della Salute e della Scienza di Torino
Turin, Italy
FORTE MRD Study Results

Moderator:

Manisha Bhutani, MD
Levine L. Cancer Institute
Charlotte, NC

Speakers:

Niccolo Bolli, MD, PhD
University Of Milan
Milan, Italy
Molecular/ Genomic Evolution of Multiple Myeloma

Irene M. Ghobrial, MD
Dana-Farber Cancer Institute
Boston, MA
Immune Microenvironment in Multiple Myeloma

Maximilian Merz, MD
Roswell Park Comprehensive Cancer Center Institute
Buffalo, NY
Intraclonal Myeloma Heterogeneity Through Single Cell Sequencing

Leif Bergsagel, MD
Mayo Clinic
Phoenix, AZ
Role of Gut Microbiota in Shaping Myeloma Evolution

Moderator:

Jens Hillengass, MD, PhD
Roswell Park
Buffalo, NY

Speakers:

Bruno Paiva, PhD
University of Navarra
Pamplona, Navarra, Spain
Flow Cytometric Measurement Issues for MRD and IP in Multiple Myeloma

David M Foureau, PhD
Levine Cancer Institute, Atrium Health
Charlotte, NC
Mass Spectrometry vs. MRD

Martin F. Kaiser, MD,FRCP,FRCPath
The Institute of Cancer Research
London, United Kingdom
Genetics and MRD

Nizar Bahlis, MD
University of Calgary
Calgary, AB, Canada
Single Cell Immune Profiling in Multiple Myeloma

Moderator:

Nina Shah, MD
UCSF Hellen Diller Family Comprehensive Cancer Center
San Francisco, CA

Speakers:

Michael O'Dwyer, MD
National University of Ireland Galway
Galway, Ireland
NK cells, An Attractive Allogeneic Cell Source for Treatment of Multiple Myeloma

Carrie Brownstein, MD
Cellectis
New York, NY
Inventing the Future of Allogeneic CAR T-Cell Therapies through Gene Editing

Marcela V. Maus, MD, PhD
Massachusetts General Hospital
Boston, MA
Novel Autologous Approaches to CAR T

Joseph Melenhorst, PhD
University of Pennsylvania
Philadelphia, PA
Immune Profiling Responders vs. Non-Responders

Sandy W. Wong, MD
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Clinical Laboratory Predictors of Durable Response

Moderator:

Saad Z. Usmani, MD,MBBS,MBA
Levine Cancer Institute
Charlotte, NC

back to top

Scientific Workshop on Interplay Between Coagulation and Malignancy

Thursday, December 3, 2020,  7:00 a.m. - 10:00 a.m. Pacific time

Co-Chair:

Lisa Baumann Kreuziger, MD
Versiti
Milwaukee, WI

NOTE: PER THE REQUEST OF THE WORKSHOP ORGANIZERS, PRESENTATIONS WILL BE AVAILABLE FOR ON-DEMAND VIEWING FOR UP TO 24HRS AFTER THE WORKSHOP AIRS.

This interactive workshop will address gaps in knowledge and ongoing investigations into the role of micro RNAs in cancer associated thrombosis, how the coagulation system affects cancer progression, and modeling of cancer associated thrombosis. Laboratory-based research and clinical biomarker studies will be the focus of the research presented.

The workshop will be divided into sessions with 3-4 talks per session. Each talk will last for 10 minutes with 10 minutes for discussion to promote interaction and collaboration. Given the desire for novel areas of investigation to be presented, presentations will be solicited using the form below.

Target Audience: The workshop is directed at basic and translational investigators interested in the mechanisms of thrombosis in cancer patients and how thrombosis may influence the progression of cancer. The interactive format and potential for identification of collaborators may also be of interest to clinically oriented investigators. We encourage participation by junior and senior investigators to facilitate mentoring opportunities also.

Objectives:

  1. To provide a unique forum to discuss the latest scientific developments in cancer and thrombosis.
  2. To enhance current collaborations, develop new collaborations, and provide opportunities for interaction between junior and established investigators in cancer and thrombosis.

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

Workshop Schedule


Moderator:

Lisa Baumann Kreuziger, MD
Versiti
Milwaukee, WI

Moderator:

Frank Slack, PhD
Beth Israel Deaconess Medical Center
Boston, MA

Speakers:

Keith R. McCrae, MD
Cleveland Clinic
Cleveland, OH
MicroRNA and Cancer Associated Thrombosis

Keith R. McCrae, MD
Cleveland Clinic
Cleveland, OH
Live Q&A

Julia Oto
Medical Research Institute Hospital La Fe
Valencia, Spain
MicroRNA to Predict Thrombosis in Pancreatic Cancer

Julia Oto
Medical Research Institute Hospital La Fe
Valencia, Spain
Live Q & A

Moderators:

Jamie M. O'Sullivan, PhD
Royal College of Surgeons In Ireland
Dublin 2, Ireland

Bethany A. Kerr, PhD
Wake Forest School of Medicine
Winston-Salem, NC

Speakers:

Laurence Panicot-Dubois
Aix Marseille University
Marseille, France
Platelets and Colorectal Progression

Laurence Panicot-Dubois
Aix Marseille University
Marseille, France
Live Q&A

Lalitha V. Nayak, MD
Case Western Reserve University
Cleveland, OH
NLF-2, Cancer, and Thrombosis

Lalitha V. Nayak, MD
Case Western Reserve University
Cleveland, OH
Live Q&A

Oluwatoyosi Muse, PhD
Beth Israel Deaconess Medical Center, Harvard Medical School
Boston, MA
The Unfolded Protein Response and Cancer Associated Thrombosis

Oluwatoyosi Muse, PhD
Beth Israel Deaconess Medical Center, Harvard Medical School
Boston, MA
Live Q&A

Janusz W. Rak, MD, PhD
McGill University
Montreal, Canada
Nano-flow Cytometry to Measure Cancer Exosomes

Janusz W. Rak, MD, PhD
McGill University
Montreal, Canada
Live Q&A

Moderators:

Deborah Siegal, MD
University of Ottawa
Ottawa, ON, Canada

John Mascarenhas, MD
Icahn School of Medicine at Mount Sinai
New York, NY

Speakers:

Joan D. Beckman, MD,PhD
University of Minnesota
Minneapolis, MN
Modeling Therapies for MPNs Using Microfluidics

Joan D. Beckman, MD,PhD
University of Minnesota Twin Cities
Minneapolis, MN
Live Q&A

Denise Jackson, PhD
RMIT University
Victoria, Australia
Tyrosine Kinase Inhibition and Thromboinflammation in MPN

Denise Jackson, PhD
RMIT University
Victoria, Australia
Live Q&A

Moderators:

Elisabeth Battinelli, MD, PhD
Brigham &amp; Woman’s Hospital
Boston, MA

Lisa Baumann Kreuziger, MD
Versiti, Blood Research Institute
Milwaukee, WI

Speakers:

Yingnan Shen, PhD
Purdue University
West Lafayette, IN
Thrombin and Fibrin Promotion of Pancreatic Cancer Growth Using Ductal Tumor Microenvironment-on-Chip

Yingnan Shen, PhD
Purdue University
West Lafayette, IN
Live Q&A

Yohei Hisada, Ph.D.
University of North Carolina at Chapel Hill
Chapel Hill, NC
Plasminogen Activator Inhibitor-1 Contributes to Venous Thrombosis in Pancreatic Cancer

Yohei Hisada, PhD
University of North Carolina Chapel Hill
Chapel Hill, NC
Live Q&A

Shadi Swaidani, MD, PhD
Cleveland Clinic
Cleveland, OH
Elevated Systemic Myeloid-Derived Suppressor Cells and Interleukin 8 Correlate with Increased Incidence of Venous Thromboembolism in Cancer Patients Receiving Immune-Checkpoint Inhibitors

Shadi Swaidani, MD, PhD
Cleveland Clinic
Cleveland, OH
Live Q&A

Yi Yang, Ph.D.
University of North Carolina Chapel Hill
Chapel Hill, NC
uPA/uPAR Axis in Both the Tumor Cell and Stromal Compartment Drives PDAC Disease Progression

Yi Yang
University of North Carolina Chapel Hill
Chapel Hill, NC
Live Q&A

Peng Zeng, MD
Case Western Reserve University
Cleveland, OH
Ponatinib Induction of Vascular Inflammation

Peng Zeng, MD
Case Western Reserve University
Cleveland, OH
Live Q&A

Moderator:

Jeffrey I. Zwicker, MD
Beth Israel Deaconess Medical Center
Boston, MA

back to top

Scientific Workshop on Translational Molecular Diagnostics in Hematology

Thursday, December 3, 2020,  2:00 p.m. - 5:00 p.m. Pacific time

Co-Chairs:

Piers Blombery, MBBS
Royal Melbourne Hospital
Melbourne, VIC, Australia

Torsten Haferlach, MD
MLL Munich Leukemia Laboratory
Munich, Germany

NOTE: PER THE REQUEST OF THE WORKSHOP ORGANIZERS, PRESENTATIONS WILL BE AVAILABLE FOR ON-DEMAND VIEWING UNTIL DECEMBER 10, 2020 at 11:59 P.M. EASTERN TIME

The detection of important genomic abnormalities in hematology (both malignant and non-malignant) to improve diagnosis and inform treatment decisions in the diagnostic laboratory has increased exponentially over the past few years. Accredited (ISO15189) diagnostic laboratories have now translated a range of complex testing across the spectrum of hematologic conditions from targeted panel testing to whole genome/transcriptome sequencing. Indeed, diagnostic laboratories are now true translational laboratories at the forefront of technological developments and making important and novel research discoveries.

Diagnostic laboratories around the world are at different stages of implementation of this complex testing and are individually confronting recurring issues including: (1) choice of technology (e.g. library preparation technology, next generation sequencing instrumentation, etc.); (2) development and implementation of appropriate bioinformatics processes; (3) standardization of variant curation, (4) dealing with novel findings; and (5) training an appropriate workforce. Diagnostic laboratories have navigated these challenges individually and as a result there is now significant heterogeneity in diagnostic practice which may act as a barrier for providing optimal patient care.

This workshop will focus on the practice of diagnostic genomics and how it is delivered and utilized in the real world. In addition, current attempts at process harmonization, technological developments and real-world genomic discoveries will be spotlighted in a highly interactive format including a molecular tumor board, guided database tours, and a showcase of novel tools.

Target Audience: This workshop is directed at those that are involved in both the delivery of molecular diagnostics as well as the end-users. As such the workshop will be relevant to those in a range of specialities and subspecialties including clinical hematologists, hematopathologists, molecular pathologists, medical laboratory scientists, clinical bioinformaticians/computational biologists, genetic counsellors and basic/translational researchers.

Objectives:

  1. To provide an interactive forum to discuss, progress and educate a broad audience around the current state of molecular diagnostics in hematology and the translation of novel technologies into routine use for patient care.
  2. Demonstrate and showcase a range of approaches from laboratories around the world to provide complex molecular testing including validation of new technologies and development of novel bioinformatic and clinical informatic software and process.
  3. Consolidate current collaborations as well as encouraging and fostering new interactions and collaborations of those in the field of molecular diagnostics around the world in order to harmonize approaches to mutual challenges in the area.
  4. Identify key shared challenges and develop a plan for collaborative solutions and future directions that advance the field of molecular diagnostics in hematology.

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

Workshop Schedule


Moderators:

Piers Blombery, MBBS
Royal Melbourne Hospital
Melbourne, VIC, Australia

Torsten Haferlach, MD
MLL Munich Leukemia Laboratory
Munich, Germany

Moderator:

Piers Blombery, MBBS
Royal Melbourne Hospital
Melbourne, VIC, Australia

Speakers:

Catherine Cargo, MB, PhD
Haematological Malignancy Diagnostic Service
Leeds, United Kingdom
Implementation Challenges of Targeted Sequencing Panels

Torsten Haferlach, MD
Munich Leukemia Laboratory GmbH
Munich, Germany
Implementation Challenges of Whole Genome Sequencing

Anna Schuh, MD
University of Oxford
Oxford, United Kingdom
Diagnostic Genomics from a Global Perspective

Moderator:

Torsten Haferlach, MD
Munich Leukemia Laboratory GmbH
Munich, Germany

Speakers:

Torsten Haferlach, MD
Munich Leukemia Laboratory GmbH
Munich, Germany
Introduction

Rashmi Kanagal-Shamanna, MD
MD Anderson Cancer Center
Houston, TX
Optical Mapping for Detection of Genomic Abnormalities in Hematologic Malignancies

David M. Kurtz, MD,PhD
Stanford University
San Francisco, CA
CAR T-cell Dynamics from Cell Free DNA Sequencing

John F Markham, PhD
Peter MacCallum Cancer Centre
Parkville, Australia
Genome-wide Copy Number Calling from Targeted Sequencing Platforms

Manja Meggendorfer, PhD
Munich Leukemia Laboratory GmbH
Munich, Germany
Whole Transcriptome Sequencing in Diagnostic Genomics

Niamh Appleby, FRCPath(Haematology)
University of Oxford
Oxford, United Kingdom
Unlocking Chronic Lymphocytic Leukemia with a Benchtop Sequencer: The Potential Future Role of Nanopore Sequencing in Molecular Diagnostics

Torsten Haferlach, MD
Munich Leukemia Laboratory GmbH
Munich, Germany
Summary

Moderator:

Kilannin Krysiak, MD
Washington University in St Louis
Saint Louis, MO

Speakers:

Kilannin Krysiak, MD
Washington University in St Louis
Saint Louis, MO
Introduction

Catherine E Cottrell, PhD
Nationwide Children's Hospital
Columbus, OH
An Overview of Germline and Somatic Variant Curation

Simone K. Feurstein, MD
University of Chicago
Ulm, Germany
Germline Curation - Worked Examples

Kilannin Krysiak, MD
Washington University in St Louis
Saint Louis, MO
Somatic Curation - Worked Examples

Alex Wagner, PhD
Nationwide Children's Hospital
Columbus, OH
Variant Classifications from the ASH Precision Medicine Somatic Working Group

Kilannin Krysiak, MD
Washington University in St Louis
Saint Louis, MO
Group Discussion

Moderator:

Michael Dickinson, MBBS,FRACP,FRCPA
Peter MacCallum Cancer Centre and Royal Melbourne Hospital
Melbourne, Australia

Co-Chair:

Piers Blombery, MBBS
Peter MacCallum Cancer Center
East Melbourne, Australia

back to top

Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure

Friday, December 4, 2020,  7:00 a.m. - 10:00 a.m. Pacific time

Co-Chair:

Marcin Wlodarski, MD, PhD
St. Jude Children's Research Hospital
Memphis, TN

NOTE: PER THE REQUEST OF THE WORKSHOP ORGANIZERS, PRESENTATIONS WILL BE AVAILABLE FOR ON-DEMAND VIEWING FOR UP TO 24HRS AFTER THE WORKSHOP AIRS.

This workshop will review the latest advances in understanding the mechanisms underlying germline predisposition to hematopoietic malignancies and bone marrow failure. Talks will concentrate on emerging data regarding recognized syndromes as well as novel susceptibility syndromes. Presentations will update attendees on the work of the ASH-ClinGen sponsored Myeloid Malignancy Variant Curation Expert Panel, which is providing gene-specific rules for functional annotation of RUNX1 and GATA2 variants. This year, there will also be an in-depth discussion about the new biology associated with deleterious germline SAMD9/SAMD9L variants.

Target Audience:

Given the increasing number of recognized syndromes, and the existence of new initiatives, this workshop will appeal to a multidisciplinary audience from many countries.

Objectives:

  1. Discuss on-going research efforts and unique scientific platforms being used to study germline susceptibility syndromes.
  2. To facilitate international collaborations among experts in the field.
  3. Promote junior scientists.
  4. Discuss novel entities and new aspects of known germline susceptibility syndromes.
  5. Educate ASH members who are clinicians on testing standards and establish a network of specialist providers for consultations and transitioning of patients.
  6. Address an ethical question regarding the care of germline mutation carriers.

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

Workshop Schedule


Moderator:

Marcin Wlodarski, MD, PhD
St. Jude Children's Research Hospital
Memphis, TN

Moderators:

Anupriya Agarwal, PhD
Oregon Health &amp; Science University
Portland, OR

Katherine Calvo, MD, PhD
National Institutes of Health
Bethesda, MD

Emery H Bresnick, PhD
University of Wisconsin
Madison, WI

Speakers:

Melanie Decker
Hannover Medical School
Hannover, Germany
Implementation of Functional Assays to Classify Runt-Related Transcription Factor 1 (RUNX1) Variants in Familial Platelet Disorder with Associated Myeloid Malignancies (RUNX1-FPD)

Melanie Decker, MSc
Hannover Medical School
Hannover, Germany
Live Q&A

Lucio H. Castilla, PhD
UMass Medical School
Worcester, MA
Predisposition to Hematologic Malignancies by Germline Runx1 Mutations in Mice

Lucio H. Castilla, PhD
UMass Medical School
Worcester, MA
Live Q&A

Amy Hsu
National Institutes of Health
Bethesda, MD
A Decade of GATA2 Deficiency: Genotype/Phenotype Emerge

Amy Hsu
National Institutes of Health
Bethesda, MD
Live Q&A

Robert R. West, Ph.D.
NIH
Bethesda, MD
The Genetic Landscape of GATA2 Deficiency

Robert R. West, Ph.D.
NIH
Bethesda, MD
Live Q&A

Alexandra Soukup, PhD
University of Wisconsin - Madison
Madison, WI
Mechanisms Underlying Disease-Causing GATA2 Enhancer Mutations

Alexandra Soukup, PhD
University of Wisconsin - Madison
Madison, WI
Live Q&A

Shai Izraeli, MD
Schneider Children's Medical Center of Israel
Petach Tikva, Israel
Phenotypic and Metabolic Characterization of GATA2 Haploinsufficient Preleukemic Progenitors

Shai Izraeli, MD
Schneider Children's Medical Center of Israel
Petach Tikva, Israel
Live Q&A

Moderators:

Devendra Hiwase, MBBS, MD, FRACP, FRCPA, PhD
Royal Adelaide Hospital and SA Pathology
Adelaide, SA, Australia

Miriam Erlacher, MD, PhD
University Medical Center Freiburg
Freiburg, Germany

Taizo A. Nakano, MD
University of Colorado School of Medicine
Denver, CO

Speakers:

Adriana Almeida De Jesus, MD, PhD
NIAID, National Institutes of Health
Bethesda, MD
Truncating Mutations in SAMD9L Cause an Early-Onset Immune-Dysregulatory Syndrome of Neutrophilic Panniculitis, Interstitial Lung Disease and Cytopenias

Adriana Almeida de Jesus, MD, PhD
NIAID, National Institutes of Health
Bethesda, MD
Live Q&A

Sushree Sangita Sahoo, PhD
St. Jude Children's Research Hospital
Memphis, TN
Genetic Spectrum of SAMD9 and SAMD9L syndromes

Sushree Sangita Sahoo, PhD
St. Jude Children's Research Hospital
Memphis, TN
Live Q&A

Jörg Cammenga, MD
Linköping University
Linköping, Sweden
Of Gains and Losses: SAMD9L Mutations in Myeloid Malignancies

Jörg Cammenga, MD
Linköping University Hospital
Linköping, Sweden
Live Q&A

Catherine Nelson, DO
Phoenix Children's Hospital
Phoenix, AZ
How to Diagnose and Manage SAMD9 and SAMD9L Syndromes?

Catherine Nelson, DO
Phoenix Children's Hospital
Phoenix, AZ
Live Q&A

Sherif Abdelhamed, PhD
St. Jude Children's Research Hospital
Memphis, TN
Modeling SAMD9L Mutation in Primary Hematopoietic Cells

Moderators:

Marcela Cavalcante De Andrade Silva, MD
Hospital Universitário Prof Alberto Antunes/Universidade Federal de Alagoas
Maceio, Brazil

Mrinal M. Patnaik, MD,MBBS
Mayo Clinic
Rochester, MN

Tim Ripperger, MD, PhD
Hannover Medical School
Hannover, Germany

Speakers:

Angela Bradbury, MD
Penn Medicine
Philadelphia, PA
Balancing Efficient Versus Effective Delivery of Genetic Services

Angela Bradbury
Penn Medicine
Philadelphia, PA
Live Q&A

Lucy Fox, MD
Peter MacCallum Cancer Centre
Melbourne, Australia
Understanding the Patient and Physician Perspective on Barriers to Optimal Care for Patients with Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure

Lucy Fox, MD
Peter MacCallum Cancer Centre
Melbourne, Australia
Live Q&A

Lori Wiener, PhD
NCI, National Institutes of Health
Bethesda, MD
Socio-economic Considerations and Quality of Life Issues in Patients with Germline Cancer Predisposition

Lori Wiener, PhD
NCI, National Institutes of Health
Bethesda, MD
Live Q&A

Sean Cryan
RUNX1 Research Program
Santa Barbara, CA
FPD from the Patient Perspective

Sean Cryan
RUNX1 Research Program
Santa Barbara, CA
Live Q&A

Moderators:

Csaba Bodor, PhD
Semmelweis University
Budapest, Hungary

Hideki Muramatsu, MD, PhD
Nagoya University Graduate School of Medicine
Nagoya, Japan

Lea C. Cunningham, MD
NCI, National Institutes of Health
Bethesda, MD

Speakers:

Mike Walsh, MD
Memorial Sloan Kettering Cancer Center
New York, NY
International Collaborations and Efforts for Gene Variant Curation

Mike Walsh, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Live Q&A

David Wu, MD, PhD
University of Washington
Seattle, WA
ASH-ClinGen Myeloid Malignancy Variant Curation

David Wu, MD, PhD
University of Washington
Seattle, WA
Live Q&A

Claire C Homan, PhD
University of South Australia
Adelaide, SA, Australia
The Somatic Mutational Landscape of Asymptomatic and Pre-leukaemic Germline RUNX1-FPDMM Carriers Determined from a Collaborative Database

Claire Homan
The University of South Australia
Adelaide, Australia
Live Q&A

Henik Hasle, MD
Aarhus University Hospital
Aarhus, Denmark
Germline GATA1 Mutation Associated with Myeloid Neoplasms and When Combined with Acquired Trisomy 21 Causes a Myeloid Leukemia like in Down Syndrome

Henik Hasle, MD
Aarhus University Hospital
Aarhus, Denmark
Live Q&A

Lisa J. McReynolds, MD, PhD
NCI, National Institutes of Health
Bethesda, MD
Risk of Cancer in Individuals with a Single Pathogenic Variant of a Fanconi Anemia Gene: a Study of Relatives

Lisa J. McReynolds, MD, PhD
NCI, National Institutes of Health
Bethesda, MD
Live Q&A

Marja Hakkarainen, MD
Helsinki University Hospital Comprehensive Cancer Center, The University of Helsinki
Helsinki, Finland
Multiple Myeloma Patients Carry a Substantial Number of Potentially Harmful Germline Variants

Marja Hakkarainen, MD
Helsinki University Hospital Comprehensive Cancer Center, The University of Helsinki
Helsinki, Finland
Live Q&A

Moderator:

Lucy A. Godley, MD,PhD
The University of Chicago
Chicago, IL

back to top

Scientific Workshop on Hematology and Pregnancy

Friday, December 4, 2020,  7:00 a.m. - 10:00 a.m. Pacific time

Co-Chair:

Henny H. Billett, MD, MSc
Montefiore Health Systems, Albert Einstein College of Medicine
Bronx, NY

NOTE: PER THE REQUEST OF THE WORKSHOP ORGANIZERS, PRESENTATIONS WILL BE AVAILABLE FOR ON-DEMAND VIEWING FOR UP TO 24HRS AFTER THE WORKSHOP AIRS.

Women with hematologic conditions can face unique challenges during pregnancy. Understanding pathophysiology of pregnancy and associated hematologic changes is paramount in optimal management of patients with bleeding and coagulation disorders, sickle cell disease and thrombotic microangiopathies associated with pregnancy. This workshop will focus on recent insights on the role that the distinctive biology of pregnancy plays on development, diagnosis, clinical course, and treatment of hematologic disorders. The workshop’s interactive format will feature brief didactic presentations from speakers on key topics, followed by question and answer session. Audience polling questions will be utilized to facilitate the interactive nature of the workshop.

Target Audience: 

This workshop would appeal to a multidisciplinary audience of basic and laboratory-based investigators and clinician researchers with an interest in pregnancy and hematology. The wide-ranging content thematic focus would be of interest to students, trainees and health care providers involved in care of pregnant and postpartum women.

Objectives:

  1. Provide a forum to present and discuss basic, translational and clinical investigations in the field of hematologic disorders in pregnancy.
  2. Foster collaboration and networking and facilitate discussion between investigators focused on pre-clinical, translational, and clinical aspects of hematologic disorders in pregnancy.
  3. Provide junior investigators opportunities to present their research and interact with established experts in the field.

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

Workshop Schedule


Moderator:

Henny H. Billett, MD, MSc
Montefiore Health Systems, Albert Einstein College of Medicine
Bronx, NY

Moderator:

Shannon M. Bates, MD,FRCPC,MSc
Department of Medicine, McMaster University
Hamilton, ON, Canada

Speakers:

Shannon M. Bates, MD,FRCPC,MSc
McMaster University
Hamilton, ON, Canada
Moderator Introduction

Michelle Sholzberg, MDCM, FRCPC, MSc
University of Toronto
Toronto, ON, Canada
Approach to Pregnancy and Delivery in Women with Bleeding Disorders

Ruchika Sharma, MD
Medical College of Wisconsin
Milwaukee, WI
Diagnosis and Management of NAIT

Leslie Skeith, MD
University of Calgary
Calgary, AB, Canada
Prevention and Treatment of Venous Thromboembolism in Pregnancy

Michelle Sholzberg, MDCM, FRCPC, MSc
University of Toronto
Toronto, ON, Canada
Panel Discussion and Live Q&A

Moderator:

Caterina P. Minniti, MD
Einstein College of Medicine
Bronx, NY

Speakers:

Caterina P. Minniti, MD
Montefiore Health Systems, Albert Einstein College of Medicine
Bronx, NY
Moderator Introduction

Lydia H. Pecker, MD
Johns Hopkins University
Baltimore, MD
Expecting More: Fertility Assessment and Preservation in Sickle Cell Disease

Eugene Oteng-Ntim, PhD, MBBS
King's College London
London, United Kingdom
Pathophysiology of SCD Complications During Pregnancy (CANCELLED)

Lydia H. Pecker, MD
Johns Hopkins University
Baltimore, MD
Panel Discussion and Live Q&A

Moderator:

Fadi Fakhouri, MBBS
ITUN, Dept Nephrology Chu Nantes, France
Nantes, France

Speakers:

Fadi Fakhouri
CHUV Lausanne
Lausanne, Switzerland
Moderator Introduction

Rasha Khoury, MD
Montefiore Health Systems, Albert Einstein College of Medicine
Bronx, NY
COVID and Pregnancy

Shruti Chaturvedi, MBBS,MS
Johns Hopkins University School of Medicine
BALTIMORE, MD
CAPS and Complement in Pregnancy

Fadi Fakhouri, MBBS
ITUN, Dept Nephrology Chu Nantes
Nantes, France
AHUS in Pregnancy

Rasha Khoury, MD
Montefiore Health Systems, Albert Einstein College of Medicine
Bronx, NY
Panel Discussion and Live Q&A

Moderator:

Irina Murakhovskaya, MD
Montefiore Medical Center, Albert Einstein College of Medicine
Bronx, NY

back to top

Scientific Workshop on What ‘Omics Are Telling Us About Molecular Mechanisms in Sickle Cell Disease

Friday, December 4, 2020,  7:00 a.m. - 10:00 a.m. Pacific time

Co-Chair:

Marilyn J. Telen, MD
Duke Univ. Med. Ctr.
Durham, NC

NOTE: PER THE REQUEST OF THE WORKSHOP ORGANIZERS, PRESENTATIONS WILL BE AVAILABLE FOR ON-DEMAND VIEWING UNTIL DECEMBER 10, 2020 at 11:59 P.M. EASTERN TIME

Sickle cell disease (SCD) is a single gene disease with extraordinarily heterogeneous outcomes. Patients have a broad spectrum of both acute and chronic disease sequelae, with attendant damage to multiple organ systems that threaten quality of life and shorten survival. Patients also show variable responses to multiple disease therapies. Initially, genetic studies started to shed light on why different patients experienced such variable disease courses, suffering from stroke, nephropathy, and cardiopulmonary disease, among others. As genetic studies have progressed from candidate SNP analysis to GWAS to whole genome sequencing, proteomics and metabolomics have also started to inform our understanding of disease pathogenesis and provide means of risk assessment. In addition, the NHLBI TOPMed program has provided whole genome sequencing for several large SCD cohorts and supports collaborative data sharing and analysis.

This workshop will now bring together people with a variety of scientific and analytical expertise and present progress to date as well as new methodologies for interpreting and integrating results obtained through various ‘omics studies. Information from these studies will not only be of interest to basic investigators striving to improve our understanding of SCD pathophysiology but also to clinical investigators interested in appropriate risk stratification and more efficient clinical study design.

Target Audience: The target audience is primarily basic and translational investigators in the field of sickle cell disease, although investigators focusing on other hemoglobinopathies and other rare single gene hematologic disorders (such as Diamond-Blackfan Anemia) should also find it informative, as will clinical investigators. The audience will hear about progress being made in using ‘omics technologies to understand SCD pathophysiology and identify potential therapeutic avenues. Exciting new analytic approaches integrating various ‘omics will be highlighted, making this workshop of great interest to early career investigators learning how to use ‘omics in their focus area. Basic investigators and clinical investigators focusing on inherited hematologic diseases are likely to find the presented research data of great interest, while methodologic presentations will be especially valuable to early career basic and translational investigators and more seasoned investigators interested in extending their work using ‘omic technologies.

Objectives:

  1. Share data demonstrating how various ‘omics technologies are contributing to our understanding of SCD pathophysiology.
  2. Raise awareness of how ‘omics technologies can inform further basic research, drug development, and clinical trial design in inherited hematologic diseases.
  3. Increase research activities using ‘omics in both basic and clinical research in hematology.

All are welcome to attend this workshop. There is no additional fee, but ASH annual meeting registration is required.

Workshop Schedule


Co-Chair:

Marilyn J. Telen, MD
Duke Univ. Med. Ctr.
Durham, NC

Moderator:

Marilyn J. Telen, MD
Duke Univ. Med. Ctr.
Durham, NC

Speakers:

Pankaj Qasba, PhD
National Institutes of Health
Bethesda, MD
Introduction to NHLBI TOPMed

Guillaume Lettre, PhD
Montreal Heart Institute Research Centre
Montreal, QC, Canada
Using Mendelian Randomization to understand clinical heterogeneity in sickle cell disease

Xu Zhang, PhD
University of Illinois At Chicago
Chicago, IL
Using Transcriptomes to Understand Hypoxic Responses in Stress Erythropoiesis in Sickle Cell Disease (SCD)—Comparing SCD to Chuvash Erythrocytosis

Ross C. Hardison, Ph.D.
The Pennsylvania State University
University Park, PA
Validated Systematic Integration of Epigenomic Data in Hematopoietic Cells (VISION): Painting the Landscape of Gene Regulation

Ambroise Wonkam, MD
University of Capetown
Cape Town, ZAF
Hydroxyurea-Induced miRNA Expression in Sickle Cell Disease

Moderator:

Allison Ashley-Koch, PhD
Duke University Medical Center
Durham, NC

Speakers:

Mark T. Gladwin, MD
University of Pittsburgh
Pittsburgh, PA
Using Multi-omics Discovery to Understand the Mechanisms of Hemolytic Anemia in Sickle Cell Disease and Transfusion Medicine

Allison Ashley-Koch, PhD
Duke University Medical Center
Durham, NC
Using Multi-omic Approaches to Dissect Pathophysiology of Sickle Cell Nephropathy

Sergei Nekhai, PhD
Howard University
Washington, DC
Urinary Proteomics and Sickle Nephropathy

Moderator:

Victor R. Gordeuk, MD
University of Illinois at Chicago
Chicago, IL

Speakers:

David C. Rees, MD
Kings College Hospital
London, United Kingdom
Effect of Hydroxyurea on Plasma Proteome

Claudia R. Morris, MD
Emory University
Atlanta, GA
Arginine Metabolome and Pain

Kalpna Gupta, PhD
University of Minnesota
Minneapolis, MN
Mechanism-based Targeting of Pain with Transcriptomics

Moderators:

Victor R. Gordeuk, MD
University of Illinois at Chicago
Chicago, IL

Allison Ashley-Koch, PhD
Duke University
Durham, NC